Navigation Links
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Date:6/9/2009

Data Findings Published in June Issue of Circulation

SILVER SPRING, Md. and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and Eli Lilly and Company (NYSE: LLY) today announced the results of a pivotal 16-week study showing that a once-daily dose of tadalafil was generally well tolerated, improved exercise capacity and improved time to clinical worsening in patients with pulmonary arterial hypertension (PAH)(1). The randomized, double-blind, 16-week, placebo-controlled Phase 3 study followed 405 patients with PAH, either treatment-naive or taking bosentan, randomized to placebo or tadalafil 2.5 mg, 10 mg, 20 mg or 40 mg orally. Results from the study entitled, "Tadalafil Therapy for Pulmonary Arterial Hypertension," were published in today's issue of Circulation.

The study formed the basis of the United States Food and Drug Administration (FDA) approval to market tadalafil tablets for the treatment of PAH under the brand name ADCIRCA(TM).

"PAH is a rare, life-threatening disease," said lead investigator Dr. Nazzareno Galie, Associate Professor of Cardiology at the University of Bologna and head of the Pulmonary Hypertension Centre at the Institute of Cardiology. "The results of this study are encouraging for PAH clinicians and the patients they treat."

About the Study

The randomized, double-blind, 16-week, placebo-controlled Phase 3 study monitored 405 patients with idiopathic PAH or PAH associated with anorexigen use, connective tissue disease, human immunodeficiency virus (HIV) infection, or congenital systemic-to-pulmonary shunts.

Patients were randomized in groups and received one of five treatments, tadala
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes JINS MEME,s ... Co., Ltd. will launch JINS MEME "ACADEMIC PACK" in late ... $5,000 (without tax /including two pairs of JINS MEME and ... solution of "JINS MEME" to academic researchers, and it enables ... electrooculography and six-axis sensors without API. (*Physiological data that can ...
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... ANDOVER, Mass. , Nov. 26, 2014 /PRNewswire/ ... AEX: PHIA) today announced expanded availability of ... including DuraDiagnost, DigitalDiagnost, MobileDiagnost wDR, MobileDiagnost Opta[i] , ... of these solutions now available in the U.S., ... global markets, the portfolio offers Philips, customers innovative ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Possible by Early Investment by Cystic Fibrosis ... ... Gilead Sciences,Inc., one of the world,s largest biopharmaceutical companies, and Parion,Sciences, ... a compound that could become an important,new drug in treating the ...
... DIEGO, Aug. 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ... development company,focused on commercializing proprietary product candidates ... today announced that the U.S. Food and,Drug ... for ANX-510,or CoFactor(R) injection, which is currently ...
Cached Medicine Technology:Promising Cystic Fibrosis Compound on Track for Development 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3
(Date:11/27/2014)... (PRWEB) November 27, 2014 An inventor ... an embarrassing fact of life, and she wants to ... few minutes later, I decided that there needed to ... she said. , Easy to use and producible in ... in a woman’s private areas throughout the day. It ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
(Date:11/27/2014)... November 27, 2014 Nearly 1,100 ... filed in a consolidated litigation now underway in ... , Documents recently updated in the Philadelphia Court ... the state proceeding, all of which involve a ... other psychiatric conditions. Many of the cases in ...
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter ... brains seem pre-wired to acquire a second language, new research ... tongue will likely gain a brain boost, the small study ... after learning," said study co-author Ping Li, co-director of the ... But it,s even more interesting, Li said, that "the brain ...
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2
... KINGSTON, R.I. -October 27, 2009Two University of Rhode Island ... discovered a technology that can detect cancerous tumors and ... cells surrounding them, thereby significantly reducing side effects. The ... grants in four years. In addition, a number of ...
... developing a range of miniaturised wearable and track-side sensors, ... British athletes improve their performance on the world stage, ... will be officially launched tomorrow (28 October 2009). ... Sensing (ESPRIT) project is funded by the EPSRC and ...
... less of a mystery, study finds. , TUESDAY, Oct. 27 ... the progression of cancer by stimulating a pathway inside cells. ... treatment of cancer, which has been linked to alcohol use ... connected to colon and breast cancer, although it,s not known ...
... N.C., Oct. 27 In conjunction with National Respiratory Care ... support and comfort industry, is proud to promote the results ... with CPAP patients daily. One of the most common ... their CPAP mask, as a result of the mask pressing ...
... SAN DIEGO, Oct. 27 Amira ... discovery and early development of new drugs to treat inflammatory ... present a company overview at the 8th Annual BIO Investor ... on Thursday, October 29, at the Palace Hotel in San ...
... Reform Included in Health Care Reform Le g ... meaningful medical liability reform and agree that changes to our ... care reform legislation passed by the Congress, according to a ... and Access. , "The HCLA poll clearly shows that ...
Cached Medicine News:Health News:URI research couple's method targets cancerous tumors 2Health News:URI research couple's method targets cancerous tumors 3Health News:URI research couple's method targets cancerous tumors 4Health News:Major research collaboration will improve British athletes' performance on world stage 2Health News:Major research collaboration will improve British athletes' performance on world stage 3Health News:Mapping the Link Between Alcohol, Cancer 2Health News:Contour Products Promotes Survey for National Respiratory Care Week, Findings Prove Benefits of Contour CPAP Pillow for Sleep Apnea Patients 2Health News:Contour Products Promotes Survey for National Respiratory Care Week, Findings Prove Benefits of Contour CPAP Pillow for Sleep Apnea Patients 3Health News:New Poll Shows Americans Want Medical Liability Reform 2
... For treatment of carpal tunnel syndrome, mild ... following cast removal. The perforated suede ... the wrist, wicking away moisture for long ... metal splint prevents painful wrist flexion, and ...
... orthotic elbow system that can be used in ... proximal ulnar fractures or post reconstructive surgery where ... highly flexible system that provides you with a ... that best fits your patients needs. Two ...
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Worn by many professional athletes, EpiTrain is our most popular elbow support....
Medicine Products: